Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer

Cancer Biomarkers

Volumn 14, Issue 4, 2014, Pages 207-214

  Lou, Emil ^a   Johnson, Melissa ^b   Sima, Camelia ^c   Gonzalez Espinoza, Rita ^c   Fleisher, Martin ^c   Kris, Mark G ^c   Azzoli, Christopher G ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarker panel; biomarkers; CYFRA 21 1; Lung cancer; SCCL Ag

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; GEMCITABINE; HUMAN EPIDIDYMIS PROTEIN 4; NEURON SPECIFIC ENOLASE; PACLITAXEL; PLASMA PROTEIN; PROGASTRIN RELEASING PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN; TESEVATINIB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTATIC LUNG CANCER; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SERUM; SMALL CELL LUNG CANCER; TUMOR DIFFERENTIATION; BLOOD; DISEASE FREE SURVIVAL; LUNG TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906715423     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140399     Document Type: Article

References (20)

1. J. Bates, R. Rutherford, M. Divilly, J. Finn, H. Grimes, I. O'Muircheartaigh and J.J. Gilmartin, Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer, Eur Respir J 10 (1997), 2535-8.
2. R. Molina, X. Filella, J.M. Auge, R. Fuentes, I. Bover, J. Rifa, V. Moreno, E. Canals, N. Vinolas, A. Marquez, E. Barreiro, J. Borras and P. Viladiu, Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors, Tumour Biol 24 (2003), 209-18.
3. Y. Yang, S. Zhao, Y. Fan, F. Zhao, Q. Liu, W. Hu, D. Liu, K. Fan and J. Wang, Detection and identification of potential biomarkers of non-small cell lung cancer, Technol Cancer Res Treat 8 (2009), 455-66.
4. R. Molina, J.M. Auge, X. Filella, N. Vinolas, J. Alicarte, J.M. Domingo and A.M. Ballesta, Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer, Anticancer Res 25 (2005), 1773-8.
5. A. Ardizzoni, M.A. Cafferata, M. Tiseo, R. Filiberti, P. Marroni, F. Grossi and M. Paganuzzi, Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer, Cancer 107 (2006), 2842-9.
6. B. Wieskopf, C. Demangeat, A. Purohit, R. Stenger, P. Gries, H. Kreisman and E. Quoix, Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role, Chest 108 (1995), 163-9.
7. F. Tas, A. Aydiner, E. Topuz, V. Yasasever, A. Karadeniz and P. Saip, Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer, J Exp Clin Cancer Res 19 (2000), 477-81.
8. R. Molina, J.M. Auge, J.M. Escudero, R. Marrades, N. Vinolas, E. Carcereny, J. Ramirez and X. Filella, Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE, Tumour Biol 29 (2008), 371-80.
9. J. Yang, M. Sa, M. Huang, Z. Xiang, B. Liu and A. Tang, The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay, Clin Biochem 46 (2013), 1705-8.
10. M.N. Holten-Andersen, I.J. Christensen, H.J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner and T. Piironen, Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay, Clin Chem 48 (2002), 1305-13.
11. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer 45 (2009), 228-47.
12. G.V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J.S. Lee, A. Mellemgaard, K. Park, S. Patil, J. Rolski, T. Goksel, F. de Marinis, L. Simms, K.P. Sugarman and D. Gandara, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-smallcell lung cancer, J Clin Oncol 26 (2008), 3543-51.
13. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, D.M. Jablons, C.J. Langer, R.F. DeVore, 3rd, J. Gaudreault, L.A. Damico, E. Holmgren and F. Kabbinavar, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall- cell lung cancer, J Clin Oncol 22 (2004), 2184-91.
14. W.D. Travis, E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, Y. Yatabe, D.G. Beer, C.A. Powell, G.J. Riely, P.E. Van Schil, K. Garg, J.H. Austin, H. Asamura, V.W. Rusch, F.R. Hirsch, G. Scagliotti, T. Mitsudomi, R.M. Huber, Y. Ishikawa, J. Jett, M. Sanchez-Cespedes, J.P. Sculier, T. Takahashi, M. Tsuboi, J. Vansteenkiste, I. Wistuba, P.C. Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B. Johnson, D. Johnson, K. Kerr, K. Kuriyama, J.S. Lee, V.A. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao and D. Yankelewitz, International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol 6 (2011), 244-85.
15. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum and D.H. Johnson, Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med 355 (2006), 2542-50.
16. N. Rekhtman, S.M. Brandt, C.S. Sigel,M.A. Friedlander, G.J. Riely, W.D. Travis, M.F. Zakowski and A.L. Moreira, Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing, J Thorac Oncol 6 (2011), 451-8.
17. R. Molina, J.M. Auge, X. Bosch, J.M. Escudero, N. Vinolas, R. Marrades, J. Ramirez, E. Carcereny and X. Filella, Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology, Tumour Biol 30 (2009), 121-9.
18. J. Kulpa, E. Wojcik, M. Reinfuss and L. Kolodziejski, Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients, Clin Chem 48 (2002), 1931-7.
19. S. Boeck, C. Wittwer, V. Heinemann, M. Haas, C. Kern, P. Stieber, D. Nagel and S. Holdenrieder, Cytokeratin 19- fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer, Br J Cancer 108 (2013), 1684-94.
20. B. Nisman, N. Heching, H. Biran, V. Barak and T. Peretz, The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuronspecific enolase in patients with advanced non-small-cell lung cancer, Tumour Biol 27 (2006), 8-16.